A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

563

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

February 3, 2017

Study Completion Date

September 13, 2017

Conditions
Low Back Pain
Interventions
DRUG

Fasinumab

Participants received fasinumab SC or IV, Q4W or Q8W.

DRUG

placebo

Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.

Trial Locations (74)

Unknown

Birmingham

Chandler

Glendale

Mesa

Phoenix

Scottsdale

Tucson

Little Rock

Beverly Hills

Carlsbad

Lakewood

Long Beach

Sacramento

San Diego

Santa Rosa

Vista

Aurora

Colorado Springs

Littleton

Washington D.C.

Clearwater

Fort Myers

Leesburg

Miami

Orlando

Chicago

Evansville

Council Bluffs

Worcester

Edina

Kansas City

St Louis

Elkhorn

Henderson

Las Vegas

Jamaica

New York

Williamsville

Cary

High Point

Raleigh

Salisbury

Wilmington

Akron

Cincinnati

Columbus

Oklahoma City

Duncansville

Anderson

Greer

Bristol

Knoxville

Cypress

Dallas

Lubbock

Plano

San Antonio

Salt Lake City

London

Toronto

Prague

Rychnov nad Kněžnou

Aalborg

Ballerup Municipality

Tallinn

Budapest

Gyula

Szolnok

Bialystok

Lodz

Lublin

Rzeszów

Warsaw

Zgierz

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02620020 - A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain | Biotech Hunter | Biotech Hunter